SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001104659-24-006837
Filing Date
2024-01-25
Accepted
2024-01-25 20:39:36
Documents
2
Period of Report
2024-01-25

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT tm244073-8_3seq1.html 3  
1 OWNERSHIP DOCUMENT tm244073-8_3seq1.xml 3 3400
2 EXHIBIT 24.1 tm244073d8_ex24-1.htm EX-24.1 8289
  Complete submission text file 0001104659-24-006837.txt   13186
Mailing Address C/O REVANCE THERAPEUTICS, INC. 7555 GATEWAY BOULEVARD NEWARK CA 94560
Business Address
Nolet Chris (Reporting) CIK: 0001782814 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-41929 | Film No.: 24563846

Mailing Address 18 CAMPUS BLVD. SUITE 100 NEWTOWN SQUARE PA 19073-3269
Business Address 18 CAMPUS BLVD. SUITE 100 NEWTOWN SQUARE PA 19073-3269 240-780-6356
ArriVent Biopharma, Inc. (Issuer) CIK: 0001868279 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)